Neurogenesis (NEUN) Stock Price & Analysis
NEUN Stock Chart & Stats
- Day’s Range
- $0.01 - $0.01
- 52-Week Range
- $0.01 - $0.01
- Previous Close
- $0.01
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $8,226
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- 0.5
- Beta
- 0.00
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Neurogenesis News
NEUN FAQ
What was Neurogenesis’s price range in the past 12 months?
What is Neurogenesis’s market cap?
When is Neurogenesis’s upcoming earnings report date?
Is Neurogenesis overvalued?
Does Neurogenesis pay dividends?
What is Neurogenesis’s EPS estimate?
How many shares outstanding does Neurogenesis have?
Which hedge fund is a major shareholder of Neurogenesis?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Neurogenesis
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm’d, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Tal Gilat
- Employees
- 307
- Website
- www.neurogenesis.com
- Address
- 1241 Butler Road, League City, TX, 77573, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 6 | 2 |
| Technical Analysis | 2 | 4 | 0 |
| Moving Averages | 2 | 2 | 2 |

